Search

Purpose: to study the clinical and laboratory efficacy of the platelet autoplasma use in the complex treatment of endogenous uveitis associated with systemic diseases accompanied by macular edema. Material and methods. The study included 46 people (72 eyes) with endogenous uveitis and macular edema. The diagnosis was made on the basis of the ophthalmological examination, including visometry, tonometry, biomicroscopy, ophthalmoscopy, perimetry, B-scan, optical coherence tomography of the macular zone, photoregistration of the anterior, posterior segment of the eye. The examination was carried out on the 1st and 10th day of treatment. The main group consisted of 22 people (36 eyes) who underwent anti-inflammatory therapy and the introduction of platelet plasma in the region of the pterygopalatine fossa. The control group consisted of 24 people (36 eyes) receiving only anti-inflammatory therapy (diprospan 0.5 paraequatorially №1, dexazone 4 mg intravenously №5, intravenous lasix 2.0 ml №5, electrophoresis with prednisolone № 7). All patients underwent the definition of IL-4, IL-6, IL-8, IL-17 in tear fluid before the study and on the 10th day. Results. The significant increase in the concentrations of pro-inflammatory cytokines (IL-17A and IL-8) and IL-4 and IL-6 involved in the development of autoimmune response and chronic inflammation was found in the patients with endogenous uveitis and macular edema. The use in the treatment of endogenous uveitis with macular edema of platelet autoplasma leads to more pronounced improvement of clinico-ophthalmological parameters (improvement in visual acuity, retinal photosensitivity, and retinal thickness reduction) relating to the comparison group. A decrease in the activity of the inflammatory process was noted in the main group after treatment, which is manifested by a significant decrease in the concentrations of IL-17A, IL-8, IL-4, IL-6, relating to the data obtained in the comparison group. The proposed scheme of complex treatment allows reducing the frequency of relapses of the pathological process.

Purpose. To analyze results of a complex treatment of ocular manifestations of rosacea using a 0.05% solution of cyclosporine for a topical application according to a scheme.Material and methods. The monitoring group consisted of 9 persons (18eyes) with a diagnosis of ophthalmic rosacea complicated by the dry eye syndrome (DES). The best corrected visual acuity (BCVA) in the group varied from 0.04 to 0.85 and averaged at 0.42. All patients underwent a complete ophthalmic examination, as well as Schirmer’s test, Norn’s test, meibomian glands disfunction (MGD) test, questionnaire. A previous topical treatment was canceled in patients of the monitoring group.Cyclosporine A (0.05%) drops were prescribed in combination with the lacrima substitutional therapy.Results. Clinical improvement occurred in 100% of cases in the form of reduced corneal syndrome, improvement of meibomian conjunctivitis, blepharitis, of secondary DES. In all cases there was a significant decrease in corneal vascularization and corneal subepithelial infiltrates. As a result of performed treatment there was an increase in visual acuity from 0.02 to 0.3 of the initial one. The mean BCVA after the treatment was 0.54. There was also a statistically significant improvement according to functional methods.Conclusions. 1. Ophthalmic rosacea is considered as a poly-etiologic disease with a complex and incompletely studied pathogenesis. 2. The above-mentioned group of patients is necessary to treat together with dermatologist to use both general and local therapy. 3. Cyclosporine A 0.05% drops usage is an effective method of local therapy in patients with ophthalmic rosacea, as it acts directly on the inflammation and the secondary DES. The main advantage of this medicine is an instillation nature of its application. 4. All patients have the objective positive results of treatment in all patients combined with subjective improvement, decrease in complaints. Patients reported an improved quality of life, that confirmes the questionnaire data.